Renaissance Group LLC Sells 7,931 Shares of Sanofi (NASDAQ:SNY)

Renaissance Group LLC trimmed its position in Sanofi (NASDAQ:SNYFree Report) by 5.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 146,155 shares of the company’s stock after selling 7,931 shares during the period. Renaissance Group LLC’s holdings in Sanofi were worth $7,954,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of SNY. Fairfield Bush & CO. bought a new position in shares of Sanofi in the 1st quarter worth $26,000. CoreCap Advisors LLC bought a new position in Sanofi during the fourth quarter worth about $27,000. Eagle Bay Advisors LLC bought a new position in Sanofi during the second quarter worth about $28,000. Disciplined Investments LLC lifted its holdings in Sanofi by 2,270.8% during the first quarter. Disciplined Investments LLC now owns 569 shares of the company’s stock worth $31,000 after acquiring an additional 545 shares in the last quarter. Finally, Ameritas Advisory Services LLC bought a new position in Sanofi during the first quarter worth about $33,000. 10.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SNY. downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 29th. HSBC initiated coverage on Sanofi in a research report on Friday, July 14th. They issued a “buy” rating on the stock. Finally, Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.33.

Get Our Latest Stock Report on Sanofi

Sanofi Price Performance

SNY traded up $0.67 during trading on Friday, hitting $53.70. 197,465 shares of the stock traded hands, compared to its average volume of 1,605,816. Sanofi has a twelve month low of $36.91 and a twelve month high of $57.82. The company has a market cap of $135.58 billion, a price-to-earnings ratio of 18.16, a PEG ratio of 1.57 and a beta of 0.57. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81. The business has a 50 day moving average price of $52.91 and a 200 day moving average price of $53.63.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.88 by $0.07. The business had revenue of $10.85 billion during the quarter, compared to the consensus estimate of $11.47 billion. Sanofi had a net margin of 16.07% and a return on equity of 27.94%. Equities research analysts forecast that Sanofi will post 4.47 earnings per share for the current fiscal year.

About Sanofi

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Articles

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.